Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D M Sullivan

Showing results (71-80 of 78) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 78 results.
Biorxiv : the Preprint Server for Biology|August 8, 2025
Novel Gain of Function Mouse Model of KCNT1-Related EpilepsySarah L Olguin, Daniel Davis, Ammara Rehman, et al.
Cancer|May 1, 1993
Long-term intravenous hydroxyurea infusions in patients with advanced cancer. A phase I trialM S Blumenreich, M J Kellihan, U G Joseph, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 20, 1994
Cloning and expression of a human P2U nucleotide receptor, a target for cystic fibrosis pharmacotherapyC E Parr, D M Sullivan, A M Paradiso, et al.
Seminars in Oncology|May 13, 1998
Defining the role of novel high-dose chemotherapy regimens for the treatment of high-risk breast cancerK K Fields, G J Elfenbein, J B Perkins, et al.
The Journal of Biological Chemistry|December 5, 1987
Purification of topoisomerase II from amsacrine-resistant P388 leukemia cells. Evidence for two forms of the enzymeF H Drake, J P Zimmerman, F L McCabe, et al.
Cancer Chemotherapy and Pharmacology|January 29, 1999
Multiple DNA repair mechanisms and alkylator resistance in the human medulloblastoma cell line D-283 Med (4-HCR)Q Dong, S P Johnson, O M Colvin, et al.
Bone Marrow Transplantation|January 31, 1998
High-dose chemotherapy and autologous peripheral blood stem cell transplantation in patients with multiple myeloma and renal insufficiencyO F Ballester, R Tummala, W E Janssen, et al.
British Journal of Cancer|October 8, 2014
A parallel-arm phase I trial of the humanised anti-IGF-1R antibody dalotuzumab in combination with the AKT inhibitor MK-2206, the mTOR inhibitor ridaforolimus, or the NOTCH inhibitor MK-0752, in patients with advanced solid tumoursI Brana, R Berger, T Golan, et al.
Pageof 8

Showing results (71-80 of 78) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 78 results.
Biorxiv : the Preprint Server for Biology|August 8, 2025
Novel Gain of Function Mouse Model of KCNT1-Related EpilepsySarah L Olguin, Daniel Davis, Ammara Rehman, et al.
Cancer|May 1, 1993
Long-term intravenous hydroxyurea infusions in patients with advanced cancer. A phase I trialM S Blumenreich, M J Kellihan, U G Joseph, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 20, 1994
Cloning and expression of a human P2U nucleotide receptor, a target for cystic fibrosis pharmacotherapyC E Parr, D M Sullivan, A M Paradiso, et al.
Seminars in Oncology|May 13, 1998
Defining the role of novel high-dose chemotherapy regimens for the treatment of high-risk breast cancerK K Fields, G J Elfenbein, J B Perkins, et al.
The Journal of Biological Chemistry|December 5, 1987
Purification of topoisomerase II from amsacrine-resistant P388 leukemia cells. Evidence for two forms of the enzymeF H Drake, J P Zimmerman, F L McCabe, et al.
Cancer Chemotherapy and Pharmacology|January 29, 1999
Multiple DNA repair mechanisms and alkylator resistance in the human medulloblastoma cell line D-283 Med (4-HCR)Q Dong, S P Johnson, O M Colvin, et al.
Bone Marrow Transplantation|January 31, 1998
High-dose chemotherapy and autologous peripheral blood stem cell transplantation in patients with multiple myeloma and renal insufficiencyO F Ballester, R Tummala, W E Janssen, et al.
British Journal of Cancer|October 8, 2014
A parallel-arm phase I trial of the humanised anti-IGF-1R antibody dalotuzumab in combination with the AKT inhibitor MK-2206, the mTOR inhibitor ridaforolimus, or the NOTCH inhibitor MK-0752, in patients with advanced solid tumoursI Brana, R Berger, T Golan, et al.
Pageof 8